Medical Microbiology Laboratory, Department of Microbiology, Alagappa University, Karaikudi, Tamil Nadu, 630008, India.
Research and Development Division, Chimertech Private Limited, Chennai, India.
Appl Biochem Biotechnol. 2022 Oct;194(10):4702-4723. doi: 10.1007/s12010-022-04072-7. Epub 2022 Jul 13.
Antimicrobial resistance issues have risen dramatically in recent years, posing a severe concern to humans worldwide. The urgent need to find novel compounds for pharmaceutical applications prompts the research of under-explored environments such as marine ecosystems. The present study was designed to discover novel secondary metabolites, and we have isolated about 30 actinomycetes from the marine soil samples collected in Thondi (Ramanathapuram, Tamil Nadu, India), where most isolates are associated with the genus Streptomyces. Out of 30, one potentially active strain (Streptomyces sp. SRMA3) was identified using primary and secondary screening methods against the drug-resistant clinical pathogens. The active metabolites extracted from the selected active isolate were subjected to partial purification and characterization using Fourier transform infrared spectrophotometer (FTIR) and gas chromatography-mass spectroscopy (GC-MS) analysis. The minimum inhibitory concentration (MIC) value was determined for the active metabolite. Further, the partially purified active fraction was revealed for its antibacterial and antibiofilm activity against drug-resistant clinical pathogens. Light and fluorescence microscopy detected the viability and adhesion of the biofilm-forming drug-resistant pathogens. Growth curve analysis showed that the active metabolite has the potential to inhibit drug-resistant pathogens. The synergistic effect of active metabolite with commercial antibiotics also revealed that it could enhance the activity of antibiotics in antimicrobial resistance pathogens. This study shows that the isolated Streptomyces sp. SRMA3 is a potentially active strain, and the metabolite derived from this strain has a good antibacterial and antibiofilm activity against antimicrobially resistant clinical pathogens and could be used for various biotechnological applications.
近年来，抗菌药物耐药性问题急剧上升，引起了全球人类的严重关注。迫切需要寻找新的化合物用于药物应用，这促使人们对海洋生态系统等未充分探索的环境进行研究。本研究旨在发现新型次级代谢产物，我们从印度泰米尔纳德邦拉马纳塔普拉姆的 Thondi 采集的海洋土壤样本中分离出约 30 株放线菌，其中大多数分离株与链霉菌属有关。在 30 株中，使用针对耐药临床病原体的初筛和复筛方法鉴定出一株具有潜在活性的菌株（链霉菌属 SRMA3）。从选定的活性分离株中提取的活性代谢产物通过傅里叶变换红外光谱（FTIR）和气相色谱-质谱（GC-MS）分析进行部分纯化和表征。测定了活性代谢物的最小抑菌浓度（MIC）值。此外，还对具有抗菌和抗生物膜活性的部分纯化活性部分进行了研究，以针对耐药临床病原体。荧光显微镜和明场显微镜检测了生物膜形成耐药病原体的活力和粘附。生长曲线分析表明，活性代谢物具有抑制耐药病原体的潜力。活性代谢物与商业抗生素的协同作用也表明，它可以增强抗生素在抗微生物耐药性病原体中的活性。这项研究表明，分离出的链霉菌属 SRMA3 是一株具有潜在活性的菌株，该菌株产生的代谢产物对具有抗菌耐药性的临床病原体具有良好的抗菌和抗生物膜活性，可用于各种生物技术应用。
